The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients.

ABSTRACT:

Objective

To assess longitudinally the antiviral immune response of T cells from patients with multiple sclerosis (MS) treated with fingolimod (FTY) vs other disease-modifying treatments (DMTs).

Methods

We assessed cellular immune responses specific to influenza virus (FLU), JC virus (JCV), and varicella-zoster virus (VZV) using quantification of interferon-γ secretion by enzyme-linked immunospot in patients with MS on FTY (n = 31), including 2 with herpes zoster (HZ), natalizumab (n = 11), and other DMTs (n = 11). We used viral lysates for FLU and VZV and a pool of peptides for FLU, JCV (VP-1), and VZV (IE63).

Results

Besides an expected drop of T cells, we found that, proportionally to the number of CD3(+) T cells, only FTY-treated patients with MS exhibited an incr

SUBMITTER: Mathias A 

PROVIDER: S-EPMC4751153 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature